期刊文献+

EZH2在卵巢癌中的研究进展 被引量:1

The research progress of EZH2 in ovarian cancer
原文传递
导出
摘要 果蝇zeste基因增强子人类同源2(enhancer of zeste homolog 2,EZH2)是近年来肿瘤领域研究的热门靶点基因,其在卵巢恶性肿瘤中表达增高,与卵巢癌的发生发展及预后密切相关。EZH2作为一种重要的负性表观遗传调控蛋白,可通过催化组蛋白3赖氨酸27三甲基化(H3K27me3)和调控新型钙黏蛋白分子CD13等影响卵巢细胞的增殖、迁移和侵袭,对EZH2的深入研究将为治疗卵巢恶性肿瘤提供新的分子靶点。本文就该领域的最新研究进展作一简要综述。 Zeste Drosophila gene enhancer human homologue 2 (EZH2) is the hotspot target gene in recent years in the field of cancer research, whose expression is increased in ovarian cancer, and it is related to the in- cidence, development and prognosis of ovarian cancer. EZH2 is a kind of important negative apparent genetic regulatory proteins, through catalytic histone 3 lysine acid 27 trimethylation (H3K27me3) and control of new calcium sticky protein molecule CD13 influence ovarian cell proliferation, migration and invasion. In-depth study of EZH2 will provide new molecular targets for the treatment of malignant ovarian tumors. This paper makes a brief summary of the latest research progress in this field.
出处 《生命的化学》 CAS CSCD 2016年第4期509-513,共5页 Chemistry of Life
基金 湖北省卫生计生西医类一般项目(WJ2015MB178) 肿瘤微环境与免疫治疗湖北省重点实验室(三峡大学)开放基金(2015KZL06)
关键词 EZH2 卵巢癌 表观遗传修饰 H3K27me3 CD13 治疗靶点 EZH2 ovarian cancer epigenetic modification H3K27me3 CD 13 therapeutic target
  • 相关文献

参考文献34

  • 1Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer inci- dence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int Cancer, 2015, 136:359-386.
  • 2Akhtar Danesh N, Lytwyn A, Elit L. Five year trends in mortality indices among gynecological cancer patients in Canada. Gynecol Oncol, 2012, 127:620-624.
  • 3Moore HM, Gonzalez ME, Toy KA, et al. EZH2 inhibi- tion decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat, 2013, 138:741-752.
  • 4Levine SS, Weiss A, Erdjument-Bromage H, et al. The core of the polycomb repressive complex is composition- ally and functionally conserved in flies and humans. Mol Cell Biol, 2002, 22:6070-6078.
  • 5Shao Z, Raible F, Mollaaghababa R, et al. Stabilization of chromatin structure by PRC 1, a Polycomb complex. Cell, 1999, 98:37-46.
  • 6Wang H, Wang L, Erdjument-Bromage H, et al. Role ofhistone H2A ubiquitination in Polycomb silencing. Na- ture, 2004, 431 : 873-878.
  • 7Wang L, Brown JL, Cao R, et al. Hierarchical recruit- ment of polycomb group silencing complexes. Mol Cell, 2004, 14:637-646.
  • 8Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisatin and revised mapping in 7q35 within the critical region for malignant myeloid disor- ders. Eur J Hum Genet, 2000, 8:174-180.
  • 9Margueron R, Li G, Sarma K, et al. Ezhl and Ezh2 main- tain repressive chromatin through different mechanisms. Mol Cell, 2008, 32:503-518.
  • 10Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature, 2011, 469:343-349.

二级参考文献56

  • 1PengGao,Geng-YinZhou,YuanLiu,Jin-SongLi,Jun-HuiZhen,Yin-PingYuan,PengGao.Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance[J].World Journal of Gastroenterology,2004,10(20):2936-2939. 被引量:19
  • 2彭燕,陈海滨,苏中静,陈玲,张锦,许丽艳.EZH2蛋白在食管癌组织中的表达[J].解剖学报,2006,37(6):650-655. 被引量:7
  • 3董桂兰,张小楠,袁文棋.EZH2和p53在乳腺癌中的表达及相关性探讨[J].中国肿瘤临床,2007,34(16):931-933. 被引量:20
  • 4康凯夫,车爱文,陈小伍,石祥呈,康子婧.PTTG和EZH2在肝癌中的表达及其临床意义[J].肿瘤学杂志,2007,13(5):394-396. 被引量:2
  • 5Cao R,Wang L,Wang H,et al.Role of histone H3 lysine 27 methylation in polycomb-group silencing[J].Science,2002,298(5595):1039-1043.
  • 6Simon J A,Lange C A.Roles of the EZH2 histone methyltransferase in cancer epigenetics[J].Mutat Res,2008,647(1/2):21-29.
  • 7Damsky C H,Richa J,Solter D,et al.Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue[J].Cell,1983,34(2):455-466.
  • 8Ito K,Yamamoto K,Kawanishi S.Manganese-mediated oxidative damage of cellular and isolated DNA by isoniazid and related hydrazines:non-Fenton-type hydroxyl radical formation[J].Biochemistry,1992,31(46):11606-11613.
  • 9Sundfeldt K,Piontkewitz Y,Ivarsson K,et al.E-cadherin expression in human epithelial ovarian cancer and normal ovary[J].Int J Cancer,1997,74(3):275-280.
  • 10Kashiwagi S,Yashiro M,Takashima T,et al.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage Ⅱ:usefulness of prognostic markers E-cadherin and Ki67[J].Breast Cancer Res,2011,13(6):R122.

共引文献23

同被引文献23

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部